GeneDx Holdings (WGS) stock surged over 46% on Tuesday after the genetic testing company reported impressive third-quarter earnings that beat expectations. The company’s revenue skyrocketed, driven by robust growth in exome and genome testing, leading to positive adjusted net income and an optimistic outlook for 2024.